Abraham S, Haufe E, Harder I, Heratizadeh A, Kleinheinz A, Wollenberg A, Weisshaar E, Augustin M, Wiemers F, Zink A, Biedermann T, Von Kiedrowski R, Hilgers M, Worm M, Pawlak M, Sticherling M, Fell I, Handrick C, Schaekel K, Staubach P, Asmussen A, Schwarz B, Bell M, Neubert K, Effendy I, Bieber T, Homey B, Gerlach B, Tchitcherina E, Stahl M, Schwichtenberg U, Rossbacher J, Buck PM, Mempel M, Beissert S, Werfel T, Weidinger S, Schmitt J (2020)
Publication Type: Journal article
Publication year: 2020
DOI: 10.1111/bjd.18958
The German atopic eczema (AE)-registry TREATgermany is a non-interventional multicenter patient cohort study for adult patients with currently moderate-to-severe disease activity or current/previous anti-inflammatory systemic treatment.1,2 Dupilumab has demonstrated to be an effective treatment for patients with moderate-to-severe AE in clinical trials.3-5 Real world evidence is now needed to evaluate its effectiveness and safety in routine care.
APA:
Abraham, S., Haufe, E., Harder, I., Heratizadeh, A., Kleinheinz, A., Wollenberg, A.,... Schmitt, J. (2020). Implementation of dupilumab in routine care of atopic eczema. Results from the German national registry TREATgermany. British Journal of Dermatology. https://doi.org/10.1111/bjd.18958
MLA:
Abraham, Susanne, et al. "Implementation of dupilumab in routine care of atopic eczema. Results from the German national registry TREATgermany." British Journal of Dermatology (2020).
BibTeX: Download